ADA: Once-weekly cagrilintide + semaglutide promising in type 2 diabetes

Three peer-reviewed studies published in The Lancet journals demonstrate that a combination therapy of once-weekly cagrilintide and semaglutide is efficacious for adults with type 2 diabetes inadequately controlled by existing treatments, representing a meaningful therapeutic advance for this population.

This does not prove the therapy will be approved by regulatory agencies, widely accessible, affordable, or effective in real-world practice outside clinical trials. Long-term safety and efficacy data may still be limited.